Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The effectiveness of influenza vaccination in preventing hospitalisation in children in Western Australia

This study aimed to determine the vaccine effectiveness of the southern hemisphere trivalent inactivated influenza vaccine (TIV) in preventing...

Research

Streptococcus pneumoniae and Haemophilus influenzae in paediatric meningitis patients at Goroka General Hospital

This research presents serotype, antimicrobial susceptibility and outcome data from paediatric meningitis patients prior to introduction of Haemophilus...

Research

A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women.

Influenza vaccination during pregnancy can prevent serious illness in expectant mothers and provide protection to newborns...

Research

Human infant memory B cell and CD4+ T cell responses to HibMenCY-TT glyco- conjugate vaccine

Carrier-specific T cell and polysaccharide-specific B cell memory responses are not well characterised in infants following glyco-conjugate vaccination.

Research

Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children

Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.

Research

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.

Research

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents

This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents.

Research

Anaphylactic Reactions During Bee Venom Immunotherapy in the Paediatric Population

A retrospective study will review episodes of anaphylaxis during bee venom immunotherapy in children, any modifications made to the dosing schedule, and the subsequent outcomes over a nine-year period in Western Australia.

Research

Erratum: Attitudes, perceptions, and experiences of Western Australians towards vaccine safety surveillance systems following COVID-19 vaccines: A qualitative descriptive study (Australian and New Zealand Journal of Public Health (2024) 48(1), (S132602002

Concerns regarding adverse events following immunisation are a barrier to vaccine uptake. Health professionals use vaccine safety surveillance systems (VSSS) to monitor vaccines and inform the public of safety data. With little known about public attitudes, perceptions, and experiences with VSSS, we examined them in the context of COVID-19 vaccinations in Western Australia.

Research

Per Os to Protection – Targeting the Oral Route to Enhance Immune-mediated Protection from Disease of the Human Newborn

Valerie Verhasselt MD, PhD Head, Immunology and Breastfeeding 0402997617 Valerie.verhasselt@thekids.org.au Head, Immunology and Breastfeeding @